{"id":"spn-810-18-mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Somnolence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SPN-810 acts as a partial agonist at the 5-HT1A receptor, a serotonin receptor subtype involved in impulse control and behavioral regulation. By enhancing serotonergic signaling through this mechanism, the drug is designed to reduce impulsive behaviors and improve executive function. This mechanism is particularly relevant for conditions characterized by impulsivity and behavioral dyscontrol.","oneSentence":"SPN-810 is a selective serotonin 5-HT1A receptor agonist that modulates serotonergic neurotransmission to reduce impulsivity and improve behavioral control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:35:58.285Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) with impulsivity in adults"}]},"trialDetails":[{"nctId":"NCT03638466","phase":"PHASE2","title":"Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD","status":"TERMINATED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2019-05-30","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression","enrollment":7},{"nctId":"NCT02691182","phase":"PHASE3","title":"Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)","status":"TERMINATED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2016-04","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":491},{"nctId":"NCT02618434","phase":"PHASE3","title":"Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2016-02-16","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":297},{"nctId":"NCT02618408","phase":"PHASE3","title":"Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2016-01-25","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":333}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SPN-810 (18 mg)","genericName":"SPN-810 (18 mg)","companyName":"Supernus Pharmaceuticals, Inc.","companyId":"supernus-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPN-810 is a selective serotonin 5-HT1A receptor agonist that modulates serotonergic neurotransmission to reduce impulsivity and improve behavioral control. Used for Attention-deficit/hyperactivity disorder (ADHD) with impulsivity in adults.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}